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Journal of Stroke and CHigh mobility group box 1 (HMGB1) elevation after cerebral ischemia activates
inflammatory pathways via receptors such as the receptor for advanced glycation
end products (RAGE) and toll-like receptors (TLRs) and leads to brain damage.
Eicosapentaenoic acid (EPA), a peroxisome proliferator–activated receptor gamma
(PPARg) agonist, attenuates postischemic inflammation and brain damage in male
animals. However, postischemic HMGB1 signaling and the effects of EPA on ovari-
ectomized (OVX1) rats remain unclear. We hypothesized that EPA attenuates brain
damage in OVX1 rats via the inhibition of HMGB1 signaling in a PPARg-dependent
manner. Seven-week-old female Sprague-Dawley rats were divided into 3 groups;
nonovariectomized (OVX2) rats and EPA-treated and EPA-untreated OVX1 rats
before cerebral ischemia induction. Another set of EPA-treated OVX1 rats was in-
jectedwith the PPARg inhibitor GW9662. OVX1 decreased themessenger RNA level
of PPARg and increased that of HMGB1, RAGE, TLR9, and tumor necrosis factor
alpha (TNFa) in parallel with ischemic brain damage. EPA restored the PPARg
expression, downregulated the HMGB1 signal–related molecules, and attenuated
the ischemic brain damage. Neither OVX1 nor EPA affected the expression of
TLR2 or TLR4. Interestingly, GW9662 partially abrogated the EPA-induced neuro-
protection and the downregulation of RAGE and TLR9. In contrast, GW9662 did
not affectHMGB1 or TNFa. These results suggest that EPA exerts PPARg-dependent
and PPARg-independent effects on postischemic HMGB1/TLR9 pathway.
The cortical infarct volume exacerbated by OVX1 is associated with the upregula-
tion of the HMGB1/TLR9 pathway. Suppression of this pathway may help to
limit ischemic brain damage in postmenopausal women. Key Words: Eicosapen-
taenoic acid—PPARg—HMGB1—RAGE—toll-like receptors—brain ischemia—
ovariectomy.
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M. SUMIYOSHI ET AL.1188Inflammation is a key element in the pathobiology of
stroke. Complex changes in the immune response after
ischemic stroke lead to systemic inflammation and an
impaired host defense.1 High mobility group box 1
(HMGB1) is a ubiquitous DNA-binding nuclear protein
that is released from necrotic cells and secreted by acti-
vated leukocytes; it has been identified as a novel
player in ischemic brain inflammation.2-5 Released
HMGB1 activates antigen-presenting cells through
the receptor for advanced glycation end products
(RAGE)6 and toll-like receptors (TLRs).7 The outcome
in male rats with experimental stroke is improved by
neutralization of HMGB1 or RAGE.8,9 This points to
the importance of regulating postischemic HMGB1
signaling in the brain.
The lack of ovarian steroid hormones renders postmen-
opausal women more vulnerable than cycling women to
cerebrovascular diseases,10 and the lipid profile affected
by menopause increases their risk for cerebral ischemic
stroke.11 Eicosapentaenoic acid (EPA), an omega-3 fatty
acid, acts as a peroxisome proliferator–activated receptor
gamma (PPARg) agonist that transcribes genes involved
in glucose and lipid homeostasis. In male animals, it
inhibits postischemic inflammation, as does the PPARg
agonist rosiglitazone.12,13 EPA prevents secondary but
not primary stroke despite elevation of the plasma
EPA/arachidonic acid (AA) ratio, which is thought to
be vasoprotective.14,15 However, the detailed mecha-
nisms underlying the beneficial effects of EPA in
ischemic stroke remain unclear, and few studies have
addressed postischemic HMGB1 signaling and the role
of EPA in ovariectomized (OVX1) rats.
Our group previously demonstrated that the expres-
sion of brain PPARg was lower in OVX1 than that in
OVX2 rats and that ischemic brain damage was larger
in OVX1 rats.16,17 Based on our and other studies, we
hypothesized that HMGB1 signaling plays an essential
role in the ischemic brain damage seen in OVX1 rats
and that EPA inhibits the activation of this pathway
and attenuates brain damage in a PPARg-dependent
manner. To examine this hypothesis, we used OVX2
rats and EPA-treated and EPA-untreated OVX1 rats. We
compared the effects of EPA administered alone or
together with the PPARg inhibitor GW9662.
We now provide new evidence that in OVX1 rats, the
postischemic HMGB1/TLR9 pathway is augmented in
parallel with the expansion of the cortical infarct volume
and that brain damage is attenuated by EPA pretreat-
ment. Interestingly, EPA inhibited RAGE and TLR9 in a
PPARg-dependent manner and HMGB1 and tumor
necrosis factor alpha (TNFa) PPARg independently. Our
findings suggest that suppression of the HMGB1/TLR9
pathway by EPA may be a promising strategy to limit
brain damage in OVX1 rats susceptible to transient cere-
bral ischemia.Materials and Methods
All experiments and protocols were approved by the
Ethics Committee of the Institute of Health Biosciences,
the University of Tokushima Graduate School and were
conducted in accordance with the National Institutes of
Health Guidelines for the Care and Use of Laboratory
Animals. Investigators involved in all surgical proce-
dures, drug treatments, and end point assessments were
blinded to the group to which each animal had been
assigned.
Animal Model and Protocol
Before inducing transient cerebral ischemia, we
randomly divided 7-week-old female Sprague-Dawley
rats (SLC, Shizuoka, Japan) into 3 groups; the first group
did not undergo ovariectomy (OVX2, n 5 12), the second
group was ovariectomized and given vehicle (VC)
perorally for 4 weeks (OVX1/VC, n 5 12), and the third
group underwent ovariectomy and received EPA
(500 mg/kg/day, perorally; Mochida Pharmaceutical
Co., Tokyo, Japan) for 4 weeks (OVX1/EPA, n 5 12).
EPAwas diluted in 5% gum arabic. To determine whether
the neuroprotective effect of EPA in OVX1 rats was
PPARg-dependent, we prepared 3 other groups of
OVX1 rats; 1 group was treated with VC (n 5 6) and
the others received EPA alone (EPA, n 5 6) or EPA plus
an intraperitoneal injection of 4 mg/kg of the PPARg
inhibitor GW9662 at 1 hour after cerebral ischemia
(EPA/GW9662, n 5 6).
At the age of 11 weeks, rats were subjected to 90-minute
middle cerebral artery occlusion (MCAO). GW9662, pur-
chased from Cayman Chemicals (Ann Arbor, MI), was
dissolved in dimethylsulfoxide, diluted 33 with saline
in .4 mL/kg, and injected (4 mg/kg, intraperitoneally)
1 hour after MCAO. The systolic, diastolic, and mean
blood pressures before MCAO were measured by tail-
cuff plethysmography (Softron, Tokyo, Japan). All surgi-
cal procedures were performed under anesthesia with
2% isofluorane in 30% oxygen and 70% nitrous oxide.
The body temperature of the animals was monitored
and maintained at 37C using a warming plate.
MCAOwas induced with a 4-0 monofilament suture as-
described previously.18,19 Blood flow to the region
surrounding the middle cerebral artery was measured
using a laser Doppler flow probe (UNIQUE MEDICAL,
Osaka, Japan) to confirm its occlusion. In all groups, the
extent of cerebral blood flow (CBF) reduction and the
increase in CBF after reperfusion were identical. A
reduction in regional CBF to less than 30% of the baseline
indicates successful MCAO. After withdrawal of the
filament, the ipsilateral blood flow was restored to
approximately 80%-100% of the baseline value in
all groups. Rats with efficient MCAO consistently
displayed circling behavior, decreased resistance to lateral
EPA INHIBITS HMGB1/TLR9 PATHWAY IN ISCHEMIC BRAIN 1189push, forelimb flexion, and shoulder adduction. Rats with
incomplete MCAO (approximately 10%) were excluded
from further experiments. The suture was withdrawn
after 90 minutes to allow reperfusion. As the cortical
infarct size and oxidative brain damage peaked at
24 hours after MCAO,20 we assessed the effect of EPA at
that time point. The plasma estradiol level was measured
by electrochemiluminescence immunoassay (Asuka Phar-
maceutical Co., Kanagawa, Japan). Using a brain matrix
(Bioresearch Center, Nagoya, Japan), extracted brain tissue
was cut into equal 2-mm spaced portions and 6 coronal
blocks were prepared; they did not contain olfactory tissue
or tissue from the cerebellum. The third coronal sections
were storedat280Cuntil use forquantitative real-timepo-
lymerase chain reaction (PCR) and Western blot analysis.
Measurement of the Infarct Volume
The rat brains were removed 24 hours after
MCAO. Sliced brain tissues were immersed in a 2,3,5-
triphenyltetrazolium chloride solution in phosphate-
buffered saline. The extent of ischemic infarction was
traced, and the integrated volume was calculated using
National Institutes of Health 1.36b ImageJ software (a
public domain image processing and analysis program
developed at the the National Institutes of Health).
Artifact from brain edema was reduced by the indirect
measurement method based on the contralateral brain
volume.21 The infarct volume was calculated as a percent-
age of the contralateral hemisphere.
Quantitative Real-Time PCR
The relative gene expression of inflammation-related
molecules in the brain cortex was determined by quanti-
tative real-time PCR (qRT-PCR) assay. Total RNA
was extracted with the EZ1 RNA Universal Tissue Kit
(QIAGEN, Tokyo, Japan) and placed in a MagNA Lyser
(Roche, Tokyo, Japan). For reverse transcription of total
RNA to complementary DNA, we used the transcriptor
first-strand complementary DNA synthesis kit (Roche).
qRT-PCR of each sample was in a LightCycler 2.0 instru-
ment (Roche Diagnostics). LightCycler FastStart DNA
master and SYBR green I (Roche) were used for
HMGB1, PPARg, TNFa, RAGE, TLR2, TLR4, TLR9, and
GAPDH. Primers for TNFa and GAPDH were from
Roche and used according to the manufacturer’s direc-
tions. The other primers were: for rat HMGB1 (forward
primer [F], 50-GAG ATC CTA AGA AGC CGA GA-30;
reverse primer [R], 50-CTT CCT CAT CCT CTT CAT
CC-30; 585 bp), for PPARg (F, 50-GCC CAG GCT TGC
TGA ACG TGA-30; R, 50-TTG GCG AAC AGC TGG
GAG GA-30; 112 bp), for RAGE (F, 50-TCA ACA TCA
GGG TCA CAG AAA C-30; R, 50-CAA TGA GCA GAG
CGG CTA-30; 129 bp), for TLR2 (F, 50-CTC CTG TGA
ACT CCT GTC CTT-30; R, 50-AGC TGT CTG GCC AGT
CAA C-30; 74 bp), for TLR4 (F, 50-TGC TAC AGT TCATCT GGG TTT CTG-30; R, 50-CTG TGA GGT CGT TGA
GGT TAG AAG-30; 78 bp), and for TLR9 (F, 50-CCG
AAG ACC TAG CCA ACC T-30; R, 50-TGA TCA CAG
CGA CGG CAA TT-30; 70 bp). The amplified product
was separated on 1.5% agarose gels containing ethidium
bromide solution (Wako, Osaka, Japan) and visualized
on an ultraviolet transilluminator. The results were quan-
tified after normalization to the expression of GAPDH
messenger RNA (mRNA). The PCR conditions were
95C for 10 minutes followed by 40 cycles at 95C for
10 seconds, 60C for 10 seconds, and 72C for 8 seconds.
We subjected samples from each group to 2 independent
qRT-PCR assays. GAPDH was the internal control.
Western Blot Analysis
Total protein in the tissues was measured with the BCA
protein assay kit (Pierce, Rockford, IL). Protein (50 mg)
was separated by 8% or 10% sodium dodecyl sulfate-
polyacrylamide gel electrophoresis and transferred to a
polyvinylidene difluoride membrane. The membrane
was blocked with 5% skim milk in Tris-buffered saline
solution Tween 20 and then incubated with primary anti-
bodies against HMGB1 (Cell Signaling Technology, MA),
TLR9 (Acris Antibodies, Inc., CA), and b-actin (Sigma,
Steinheim, Germany) in Tris-buffered saline solution
Tween 20 or Can Get signal immunoreaction enhan-
cer solution (Toyobo, Osaka, Japan). After incubation
with horseradish peroxidase–conjugated secondary anti-
bodies, signals were detected by chemiluminescence
using an ECL prime Western blotting detection reagent
(GE Healthcare, Buckinghamshire, UK). Images were
detected using Image Quant Las 4000 mini (GE Health-
care, Tokyo, Japan) and analyzed with image software
from ImageJ and quantified as the relative increase over
the controls after normalization with b-actin.
Statistical Analysis
Sequentially obtained data (mean 6 standard devia-
tion) were analyzed with the Student t test for 2-group
comparisons and analysis of variance followed by
Scheffe’s test for multiple comparisons. Statistical ana-
lyses were performed on a Windows computer running
statistical software (StatView 5). Differences of P less
than .05 were considered statistically significant.
Results
EPAAttenuated the Increase in HMGB1 and TNFa and
the Decrease in PPARg in OVX1 Rats Susceptible to
Ischemic Brain Damage
First, we examined the plasma EPA/AA ratio, estradiol
level, and body weight (BW) of OVX2 rats and OVX1 rats
treated with VC or EPA. Although the plasma EPA/AA
ratio was not affected by OVX alone (Fig 1, A), it
was increased in EPA-treated OVX1 rats. Plasma estra-
diol was significantly lower in OVX1 rats than that in
Figure 1. Effects of eicosapentaenoic acid
(EPA) on the plasma EPA/arachidonic acid
(AA) ratio, the estradiol level, and BW. Before
drug administration, the rats were randomly
divided into 3 groups; nonovariectomized
(OVX2) rats and ovariectomized (OVX1) rats
received EPA (500 mg/kg/day; OVX1/EPA);
the controls received vehicle (VC; OVX1/VC).
There was no significant difference in the BW
between 3 groups. Four weeks later, they were
subjected to 90-minute middle cerebral artery
occlusion (MCAO). Plasma samples were
collected 24 hours after MCAO, and the plasma
EPA/AA ratio (A) and the estradiol level (B)
were determined. The BW was measured every
day and recorded just before MCAO induction
(C). Each bar represents the mean 6 standard deviation (each group n 5 12). *P , .05 versus OVX2 by analysis of variance followed by Scheffe’s test,
†P , .05 versus OVX1/VC by the Student t test.
M. SUMIYOSHI ET AL.1190OVX2 rats and not affected by EPA (Fig 1, B). BW was
significantly higher in OVX1 rats than that in OVX2
rats; it was lower in EPA-treated than EPA-untreated
OVX1 rats (Fig 1, C). Neither OVX nor EPA affected the
food intake (data not shown). This observation coincides
with the findings of Kasbi et al22 that EPA reversed a sig-
nificant BW increase in hamsters fed with a high-fat diet
and suggests the systemic improvement of glucose and
lipid metabolism in a PPARg-dependent manner.
Next, we examined the relationship between the
HMGB1 signaling pathway and brain damage after tran-
sient cerebral ischemia. The infarct volume in the cortex
but not the basal ganglia region was significantly larger
in OVX1 rats than OVX2 rats (Fig 2, A). The corticalinfarct volume was significantly smaller in EPA-treated
than EPA-untreated OVX1 rats. Correlated with the
infarct volume, the mRNA level of HMGB1 (Fig 2, B)
and TNFa (Fig 2, C) in the cortex was increased in
OVX1/VC rats and decreased by EPA. In contrast, the
mRNA level of PPARg was reduced in OVX1/VC rats
and restored by EPA (Fig 2, D). These results suggest
that HMGB1 signaling, PPARg, and ischemic brain dam-
age are closely linked in female rats and that EPA may be
useful to limit ischemic brain damage even under
estrogen-deficient conditions. The plasma EPA/AA ratio
did not necessarily reflect the infarct volume in our rats.
EPA affected neither the CBF nor the blood pressure
before, during, and after MCAO (data not shown).Figure 2. Effects of EPA on postischemic
brain damage and the mRNA level of HMGB,
TNFa, and PPARg in OVX1 rats. The infarct
volume (A) is shown as a percentage of the
contralateral hemisphere in OVX2, OVX1/
VC, and OVX1/EPA rats (each group
n 5 12). The mRNA level of HMGB1 (B),
TNFa (C), and PPARg (D) was determined
by quantitative real-time polymerase chain reac-
tion and normalized by the GAPDH mRNA
level (each group n 5 6). Each bar indicates
the mean6 standard deviation. *P, .05 versus
OVX2 by analysis of variance followed by
Scheffe’s test, †P , .05 versus OVX1/VC by
the Student t test. Abbreviations: EPA, eicosa-
pentaenoic acid; HMGB1, high mobility group
box 1; mRNA, messenger RNA; OVX1, ovari-
ectomized rats; OVX2, nonovariectomized rats;
PPARg, peroxisome proliferator–activated re-
ceptor gamma; TNFa, tumor necrosis factor
alpha; VC, vehicle.
Figure 3. Effects of EPA on the mRNA level
of TLRs and RAGE. The cortical mRNA level
of TLR2 (A), TLR4 (B), TLR9 (C), and RAGE
(D) was assayed by quantitative real-time poly-
merase chain reaction and normalized by the
GAPDH mRNA level. Each bar indicates the
mean 6 standard deviation (each group
n 5 6). *P , .05 versus OVX2 by analysis of
variance followed by Scheffe’s test, †P , .05
versus OVX1/VC by the Student t test. Abbre-
viations: EPA, eicosapentaenoic acid; mRNA,
messenger RNA; OVX1, ovariectomized rats;
OVX2, nonovariectomized rats; RAGE, recep-
tor for advanced glycation end products; TLR,
toll-like receptor; VC, vehicle.
EPA INHIBITS HMGB1/TLR9 PATHWAY IN ISCHEMIC BRAIN 1191EPA Attenuated the Elevated Expression of RAGE and
TLR9 in OVX1Rats; the Expression of TLR2 and TLR4
Was not Affected by OVX or EPA
We further examined the relationship between ischemic
brain damage and the postischemic mRNA level of
RAGE and TLRs in OVX2 rats and EPA-treated and
EPA-untreated OVX1 rats. Although in male rats the
expression of TLR2 and TLR4 increased after cerebral
ischemia,23,24 their expression in our rats was not
affected by OVX nor by EPA treatment in OVX1 rats
(Fig 3, A,B). On the other hand, the mRNA level of
TLR9 and RAGE was significantly increased by OVX
and attenuated by EPA (Fig 3, C,D), indicating that the
upregulation of TLR9 and RAGE is also associated with
the ischemic brain damage in OVX1 rats and EPA helps
to attenuate it. These results suggest that HMGB1/TLR9
pathway may play an essential role to exacerbate the
ischemic brain damage in OVX1 rats.EPA Inhibited the HMGB1/TLR9 Pathway PPARg
Dependently and Independently
To study the mechanisms underlying the EPA-induced
inhibition of the HMGB1/TLR9 pathway in OVX1 rats,
we focused on PPARg. The EPA-induced reduction in
the cortical infarct volume was partially abolished by
the PPARg inhibitor GW9662 (Fig 4, A). Western blot anal-ysis showed that while the EPA-induced reduction of
HMGB1 was not affected by GW9662, the EPA-induced
reduction of TLR9 was abrogated by GW9662 (Fig 4, B).
In addition, whereas GW9662 did not affect the mRNA
level of HMGB1 and TNFa, it partly abolished the EPA-
induced reduction of RAGE and TLR9 (Fig 5, A-D). In
VC rats, GW96662 exerted no significant effect on the
mRNA level of these molecules (data not shown). Conse-
quently, we posit that EPA regulates the HMGB1/TLR9
pathway bidirectionally in the postischemic cerebral cor-
tex and that the downregulation of HMGB1 and TNFa is
PPARg-independent, whereas the downregulation of
RAGE and TLR9 is PPARg-dependent (Fig 6). Thus,
EPA treatment may attenuate postischemic inflammation
and brain damage in OVX1 rats.Discussion
The activation of HMGB1 signaling plays a crucial role
in postischemic inflammation and brain damage. Few
studies have investigated HMGB1 signaling and its regu-
lation by EPA in OVX1 rats. Here, we first demonstrate
that OVX increases the expression of HMGB1, TNFa,
RAGE, and TLR9 in the cerebral cortex of rats subjected
to cerebral ischemia. We also show that EPA pretreatment
attenuates these changes irrespective of the estrogen
level. The changes in the inflammation-related molecules
Figure 4. The effects of EPA-induced PPARg
activation on ischemic brain damage and
HMGB1/TLR9 pathway. OVX1 rats were sub-
jected to 90-minute MCAO. They received VC,
EPA, or EPA plus the PPARg inhibitor
GW9662 (EPA/GW9662). GW9662 (4 mg/kg)
was injected intraperitoneally 1 hour after
MCAO. At 24 hours after MCAO, the cortical
infarct volume (A) was measured and the
expression of HMGB1 and TLR9 in the cortex
(B) was determined by Western blot analysis.
Each bar represents the mean 6 standard devi-
ation (each group n 5 6). *P , .05 versus VC
by analysis of variance followed by Scheffe’s
test, †P , .05 versus EPA by the Student t
test. Abbreviations: EPA, eicosapentaenoic
acid; HMGB1, high mobility group box 1;
MCAO, middle cerebral artery occlusion;
mRNA, messenger RNA; OVX1, ovariecto-
mized rats; PPARg, peroxisome proliferator–
activated receptor gamma; TLR, toll-like recep-
tor; VC, vehicle.
M. SUMIYOSHI ET AL.1192HMGB1, TNFa, RAGE, and TLR9 were in parallel with
the cortical infarct volume. Although in male animals,
TLR2 and TLR4 play a role in cerebral ischemia,2 in our
rats, their expression was not affected by OVX or EPA.
Of particular interest is our observation that the neuro-
protective effects of EPA were associated with itsPPARg-independent inhibition of HMGB1 and TNFa
and its PPARg-dependent inhibition of RAGE and
TLR9. Thus, ours is the first documentation that OVX
augments postischemic HMGB1/TLR9 pathway and
brain damage and that EPA modifies this augmented
HMGB1 signaling and exerts neuroprotective effects.Figure 5. EPA-induced inhibition of
HMGB1/TLR9 pathways occurs PPARg depen-
dently and independently. OVX1 rats received
VC, EPA, or EPA plus the PPARg inhibitor
GW9662 (EPA/GW9662). VC and EPA were
administered perorally for 4 weeks before
MCAO induction. GW9662 (4 mg/kg) was
injected intraperitoneally at 1 hour after
MCAO. The mRNA level of HMGB1 (A),
TNFa (B), RAGE (C), and TLR9 (D) was as-
sayed by quantitative real-time polymerase
chain reaction and normalized by the GAPDH
mRNA level. Each bar represents the
mean 6 standard deviation (each group
n 5 6). *P , .05 versus VC by analysis of vari-
ance followed by Scheffe’s test, †P , .05 versus
EPA by the Student t test. Abbreviations: EPA,
eicosapentaenoic acid; HMGB1, high mobility
group box 1; MCAO, middle cerebral artery
occlusion; mRNA, messenger RNA; OVX1,
ovariectomized rats; PPARg, peroxisome prolif-
erator–activated receptor gamma; RAGE, recep-
tor for advanced glycation end products; TLR,
toll-like receptor; TNFa, tumor necrosis factor
alpha; VC, vehicle.
Figure 6. Schematic representation of the effects of EPA on the HMGB1/
TLR9 pathway in OVX1 rats subjected to transient cerebral ischemia. The
expression of HMGB1, its receptors RAGE and TLR9, and TNFa was
augmented in OVX1 rats subjected to cerebral ischemia, resulting in brain
damage. EPA pretreatment inhibited the activation of the HMGB1/TLR9
pathway in a PPARg-dependent and PPARg-independent manner. EPA pre-
treatment attenuated postischemic inflammatory responses and brain dam-
age even in estrogen-deficient rats susceptible to ischemic brain damage.
Abbreviations: EPA, eicosapentaenoic acid; HMGB1, high mobility group
box 1; mRNA,messenger RNA; OVX1, ovariectomized rats; PPARg, perox-
isome proliferator–activated receptor gamma; RAGE, receptor for advanced
glycation end products; TLR, toll-like receptor; TNFa, tumor necrosis factor
alpha.
EPA INHIBITS HMGB1/TLR9 PATHWAY IN ISCHEMIC BRAIN 1193Inhibition of the postischemic HMGB1/TLR9 pathway
may be a therapeutic target in patients with ischemic
stroke, especially postmenopausal women.
In male animals, HMGB1 induces the release of
cytokines via a mechanism that depends on RAGE,
TLR4, and at least in part on TLR2.3,7,8 Although the
postischemic expression of HMGB1, RAGE, and TLR9
was augmented by OVX and attenuated by EPA that of
TLR2 and TLR4 was not. TLRs are key receptors in the
innate immune response to infectious microorganisms
including lipids and nucleic acids, and they are
activated by host-derived molecules and associated with
ischemic inflammatory injury.7 We do not know why
the expression of TLR2 and TLR4 is different between
male and female animals although Roberts et al25 re-
ported that in mice Coxsakie virus–induced autoimmune
myocarditis, there is a sex difference in their expression.
Cytokines can modulate TLR expression and sex hor-
mones alter cytokine responses with estradiol and testos-
terone having distinct effects on proinflammatory and
anti-inflammatory cytokines.26 TLR expression profiles
may vary between the sexes.
On the other hand, RAGE, a multiligand-binding mem-
ber of the immunoglobulin superfamily, is expressed on
multiple cell types including inflammatory cells and
neurons.6 It activates signal transduction cascades andme-
diates ischemic brain damage.8 TLR9 recognizes
unmethylated CpG-containing DNA sequences. TLR9
senses unmethylated CpG dinucleotides that can bemimicked by synthetic oligonucleotides containing CpG
motifs (CpG ODNs). Tian et al27 demonstrated that class
A CpG-containing oligodeoxynucleotides and HMGB1
interact functionally and that the resultant complex aug-
ments the interaction between RAGE and TLR9 and stimu-
lates cytokineproduction throughaTLR9-MyD88pathway.
Theirs support our findings that the upregulation of
HMGB1 is associated with the upregulation of RAGE and
TLR9 and strengthen our hypothesis that in OVX1 rats
the HMGB1/TLR9 pathway plays an essential role in the
exacerbation of postischemic brain damage (Fig 6).
The expression of TLR7 and TLR8 tends to be associated
with a poor stroke outcome.28 However, TLR7 precondi-
tioning promoted tolerance to ischemic brain injury in
mice29 and the systemic administration of TLR4, TLR7,
and TLR9 before the manifestation of cerebral ischemia
reduced ischemic injury by reprogramming the response
of the brain to stroke.30 Furthermore, HMGB1 plays a
limited role in postischemic macrophage activation,31 and
astrocytic HMGB1 promotes neurovascular remodeling
during stroke recovery.32 As it is unclear whether HMGB1
initiates the inflammatory response or merely reflects
leukocyte activation by another signal,33 HMGB1 signaling
may be affected by postischemic conditions.
EPA not only acts as a PPARg agonist, it also has
antiarrhythmic, anticoagulant, antioxidant, and anti-
inflammatory effects. PPARg modulates the central
nervous immune system by inhibiting the activation of
macrophage/microglia and by modulating the release
of proinflammatory mediators.34 Therefore, we hypo-
thesized that EPA acts in a PPARg-dependent manner.
Unexpectedly, the neuroprotective effects of EPA were
associated with its PPARg-independent inhibition of
HMGB1 and TNFa and its PPARg-dependent inhibition
of RAGE and TLR9. The observation that omega-3 fatty
acids attenuate dendritic cell function via NF-kB indepen-
dent of PPARg35 supports the existence of PPARg-depen-
dent and PPARg-independent EPA effects.
Tanaka et al14 found that EPA effectively prevented sec-
ondary stroke. The EPA-induced increase in the plasma
EPA/AA ratio is considered to be vasoprotective in hu-
mans. The plasma EPA/AA ratio in our OVX1 rats was
not necessarily associatedwith the size of the cortical infarct
volume, although EPA increased the plasma EPA/AA
ratio. Lancette-Hebert et al36 reported that the accumula-
tion of dietary docosahexaenoic acid (DHA) in the brain
attenuates postischemic neuronal damage and Sekikawa
et al37 demonstrated that it has a more potent antiathero-
genic effect in men than that in women. Because most
EPA can be converted to DHA, a dietary intake or supple-
mentation of EPA can be expected to increase DHA in the
brain. Therefore, the neuroprotective effects of EPA may
be attributable to the accumulated DHA in the brain rather
than the elevation of the plasma EPA/AA ratio.
Our study has some limitations. We did not use the
aged rats. We did not examine the brain DHA level in
M. SUMIYOSHI ET AL.1194our rats. We do not know the detailed role of each TLR.
We need further studies to elucidate the precise mecha-
nisms underlying the neuroprotective effect of EPA we
observed in our animals.
In the present study, we provide the new insight that
in OVX1 rats, activation of the brain HMGB1/TLR9
pathway may play an essential role in postischemic
inflammation and brain damage. EPA pretreatment atten-
uated activation of the postischemic HMGB1/TLR9
pathway PPARg dependently and independently and
prevented postischemic neuronal damage without
affecting the estrogen level. Based on our findings, we
suggest that EPA pretreatment attenuates postischemic
inflammation and brain damage even under estrogen-
deficient conditions.
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